Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)
NCT06413433 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)
- Lead sponsor
- Axsome Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- April 26, 2024
- Completion date
- December 31, 2026
- Enrollment
- 450 (estimated)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.